BrainStorm Cell Therapeutics (BCLI) announced that it has signed a Letter of Intent, or LOI, with Minaris Advanced Therapies, a global contract development and manufacturing organization, or CDMO, specializing in cell and gene therapies, to manufacture NurOwn for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn in preparation for clinical trial manufacturing at Minaris’ state-of-the-art facility in Allendale, New Jersey. This partnership supports BrainStorm’s readiness for its planned Phase 3b clinical trial. This partnership enhances BrainStorm’s U.S. based manufacturing capabilities and supports its multicenter Phase 3b clinical trial in the United States. It complements BrainStorm’s recently announced collaboration with Pluri (PLUR) ( PLUR) in Israel, which will also contribute to the production of clinical trial material. Together, these strategic relationships reinforce BrainStorm’s commitment to building a robust and flexible manufacturing network to advance the clinical development of NurOwn.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCLI:
- Biotech Alert: Searches spiking for these stocks today
- Buy Rating for BrainStorm Cell Therapeutics: Strategic Advancements and Promising ALS Therapy Developments
- Brainstorm Cell Therapeutics Reports Q1 2025 Financials
- Brainstorm Cell Therapeutics: Progress and Challenges in ALS Trial
- One new option listing and nine option delistings on May 19th
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue